Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

202159 citationsJournal Articlehybrid Open Access

Authors

Scott T. Tagawa · Cornell University

Krishnan Ramaswamy · Pfizer (United States)

Ahong Huang · STATinMED (United States)

Jack Mardekian · Pfizer (United States)

Neil M. Schultz · Astellas Pharma (United States)

Li Wang · STATinMED (United States)

Rickard Sandin ·

Abstract

Retrospective analysis of the VHA database indicated that chemotherapy-naive patients with mCRPC initiating therapy with enzalutamide had improved survival versus abiraterone.

Topics & Keywords

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Cancer, Lipids, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Prostate Cancer and Prostatic Diseases

Volume 24, Issue 4, pp. 1032-1040

DOI: 10.1038/s41391-021-00318-3

Field-Weighted Citation Impact: 6.60